An Open Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, An Anti-CD20 X Anti-CD3 Bispecific Antibody in Patients with Relapsed/Refractory Follicular Lymphoma (R19179-ONC-1625)
An Open Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, An Anti-CD20 X Anti-CD3 Bispecific Antibody in Patients with Relapsed/Refractory Follicular Lymphoma (R19179-ONC-1625)
Trial Category:
Lymphoma
Contact(s)
Location(s)
Nebraska Cancer Specialists, Omaha, NE
